Skip to main content
Erschienen in: Current Treatment Options in Cardiovascular Medicine 3/2011

01.06.2011 | Cerebrovascular Disease and Stroke

Basilar Branch Occlusion

verfasst von: Jaime Gállego Culleré, MD, PhD, María Elena Erro Aguirre, MD, PhD

Erschienen in: Current Treatment Options in Cardiovascular Medicine | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Opinion statement

During the past few years, the branch syndromes have been ascribed to pontine lesions, and the development of neuroimaging techniques has renewed the interest in exploring their clinical–radiological correlation. Brain imaging via MRI has helped in the diagnosis and accurate localization of lesions. From classic studies it is now accepted that the pathogenic mechanism of lacunar pontine infarction (LPI) is perforating small arterial disease or microangiopathy caused by lipohyalinosis, whereas paramedian pontine infarction (PPI) are caused by paramedian or circumferential basilar branch disease due to atheromatous branch occlusion. The importance of basilar artery disease not only in severe posterior circulation infarcts but also in minor brainstem strokes is known from previous reports. The mechanism of PPI is probably local occlusion of the mouths of paramedian perforators through the atheromatous basilar artery (basilar branch occlusion). Infrequent basilar artery diseases such as dissection, aneurysm and hypoplasia, dolichoectatic basilar artery, embolism, or vasospasms are known to block the orifices of penetrating branch arteries and cause an infarct in the territory of the obstructed branches. An association between basilar artery branch disease and isolated pontine infarction exists; moreover, the enlargement of pontine lesion seems to be associated with neurologic worsening and fluctuating symptoms, but we know little about stroke mechanisms in patients with fluctuating symptoms and about the role of branch atherosclerotic disease. The treatment remains controversial, even in acute cases. Implementation of new neuroimaging techniques, such as high-resolution MRI, could be helpful in identifying pathogenetic mechanisms of isolated pontine infarction, thus improving therapeutic strategy and secondary prevention.
Literatur
1.
Zurück zum Zitat Bassetti C, Bogousslavsky J, Barth A, Regli F. Paramedian pontine infarct: clinical–topographical correlation. Neurology. 1996;46:165–75.PubMed Bassetti C, Bogousslavsky J, Barth A, Regli F. Paramedian pontine infarct: clinical–topographical correlation. Neurology. 1996;46:165–75.PubMed
2.
Zurück zum Zitat Fisher CM, Curry HB. Pure motor hemiplegia of vascular origin. Arch Neurol. 1965;13:30–44.PubMed Fisher CM, Curry HB. Pure motor hemiplegia of vascular origin. Arch Neurol. 1965;13:30–44.PubMed
3.
Zurück zum Zitat Fisher CM, Caplan LR. Basilar artery branch occlusion: a cause of pontine infarction. Neurology. 1971;21:900–5.PubMed Fisher CM, Caplan LR. Basilar artery branch occlusion: a cause of pontine infarction. Neurology. 1971;21:900–5.PubMed
4.
Zurück zum Zitat Caplan LR. Intracranial branch atheromatous disease: a neglected, understudied, and underused concept. Neurology. 1989;39:1246–50.PubMed Caplan LR. Intracranial branch atheromatous disease: a neglected, understudied, and underused concept. Neurology. 1989;39:1246–50.PubMed
5.
Zurück zum Zitat Caplan L. Posterior circulation disease: clinical findings, diagnosis and management. In: Blackwell Science, editors. Penetrating branch artery and lacunar stroke. 1996. pp. 381–443. Caplan L. Posterior circulation disease: clinical findings, diagnosis and management. In: Blackwell Science, editors. Penetrating branch artery and lacunar stroke. 1996. pp. 381–443.
6.
Zurück zum Zitat Caplan LR, Wityk RJ, Glass TA, Tapia J, et al. New England Medical Center posterior circulation registry. Ann Neurol. 2004;56:389–98.PubMedCrossRef Caplan LR, Wityk RJ, Glass TA, Tapia J, et al. New England Medical Center posterior circulation registry. Ann Neurol. 2004;56:389–98.PubMedCrossRef
7.
Zurück zum Zitat Erro ME, Gállego J, Herrera M, Bermejo B. Isolated pontine infarcts: etiopathogenic mechanisms. Eur J Neurol. 2005;12:984–8.PubMedCrossRef Erro ME, Gállego J, Herrera M, Bermejo B. Isolated pontine infarcts: etiopathogenic mechanisms. Eur J Neurol. 2005;12:984–8.PubMedCrossRef
8.
Zurück zum Zitat Tatsumi S, Yamamoto T. An autopsied case of an apparent pontine branch atheromatous disease. Eur Neurol. 2010;63:184–5.PubMedCrossRef Tatsumi S, Yamamoto T. An autopsied case of an apparent pontine branch atheromatous disease. Eur Neurol. 2010;63:184–5.PubMedCrossRef
9.
Zurück zum Zitat Bogousslavsky J, Regli F, Maeder P, et al. The etiology of posterior circulation infarcts: a prospective study using magnetic resonance imaging and magnetic resonance angiography. Neurology. 1993;43:1528–33.PubMed Bogousslavsky J, Regli F, Maeder P, et al. The etiology of posterior circulation infarcts: a prospective study using magnetic resonance imaging and magnetic resonance angiography. Neurology. 1993;43:1528–33.PubMed
10.•
Zurück zum Zitat Kwon HM, Kim JH, Lim JS, et al. Basilar artery dolichoectasia is associated with paramedian pontine infarction. Cerebrovasc Dis. 2009;27:114–8.PubMedCrossRef Kwon HM, Kim JH, Lim JS, et al. Basilar artery dolichoectasia is associated with paramedian pontine infarction. Cerebrovasc Dis. 2009;27:114–8.PubMedCrossRef
11.
Zurück zum Zitat Mayor S, Erro ME, Zazpe I, Gállego J. Pontine stroke due to vasospasm secondary to perimesencephalic subarachnoid hemorrhage. Neurologia. 2008;23:256–8.PubMed Mayor S, Erro ME, Zazpe I, Gállego J. Pontine stroke due to vasospasm secondary to perimesencephalic subarachnoid hemorrhage. Neurologia. 2008;23:256–8.PubMed
12.
Zurück zum Zitat Mandava P, Bebensee A, Rawlings RR, Kent TA. Basilar artery aneurysm thrombosis. Neurology. 2002;59:1287.PubMed Mandava P, Bebensee A, Rawlings RR, Kent TA. Basilar artery aneurysm thrombosis. Neurology. 2002;59:1287.PubMed
13.
Zurück zum Zitat Zandio Amorena B, Erro Aguirre ME, Cabada T, Ayuso Blanco T. Cocaine-induced brain stem stroke associated to cranial midline destructive lesions. Neurologia. 2008;23:55–8.PubMed Zandio Amorena B, Erro Aguirre ME, Cabada T, Ayuso Blanco T. Cocaine-induced brain stem stroke associated to cranial midline destructive lesions. Neurologia. 2008;23:55–8.PubMed
14.
Zurück zum Zitat Kumral E, Bayülkem G, Evyapan D. Clinical spectrum of pontine infarction. Clinical-MRI correlations. J Neurol. 2002;249:1659–70.PubMedCrossRef Kumral E, Bayülkem G, Evyapan D. Clinical spectrum of pontine infarction. Clinical-MRI correlations. J Neurol. 2002;249:1659–70.PubMedCrossRef
15.
Zurück zum Zitat Farrar J, Donnan GA. Capsular warning syndrome preceding pontine infarction. Stroke. 1993;24:762.PubMed Farrar J, Donnan GA. Capsular warning syndrome preceding pontine infarction. Stroke. 1993;24:762.PubMed
16.
Zurück zum Zitat Klein IF, Lavallée PC, Schouman-Claeys E, Amarenco P. High-resolution MRI identifies basilar artery plaques in paramedian pontine infarct. Neurology. 2005;64(3):551–2.PubMed Klein IF, Lavallée PC, Schouman-Claeys E, Amarenco P. High-resolution MRI identifies basilar artery plaques in paramedian pontine infarct. Neurology. 2005;64(3):551–2.PubMed
17.••
Zurück zum Zitat Klein IF, Lavallée PC, Mazighi M, et al. Basilar artery atherosclerotic plaques in paramedian and lacunar pontine infarctions: a high-resolution MRI study. Stroke. 2010;41:1405–9.PubMedCrossRef Klein IF, Lavallée PC, Mazighi M, et al. Basilar artery atherosclerotic plaques in paramedian and lacunar pontine infarctions: a high-resolution MRI study. Stroke. 2010;41:1405–9.PubMedCrossRef
18.•
Zurück zum Zitat Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. Classification of stroke subtypes. Cerebrovasc Dis. 2009;27:493–501.PubMedCrossRef Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. Classification of stroke subtypes. Cerebrovasc Dis. 2009;27:493–501.PubMedCrossRef
19.•
Zurück zum Zitat Kirshner HS. Current issues in antiplatelet therapy for stroke prevention: the importance of stroke subtypes and differences between stroke and MI patients. J Neurol. 2010;257:1788–97.PubMedCrossRef Kirshner HS. Current issues in antiplatelet therapy for stroke prevention: the importance of stroke subtypes and differences between stroke and MI patients. J Neurol. 2010;257:1788–97.PubMedCrossRef
20.
Zurück zum Zitat US Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med. 2004;140:554–6. US Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med. 2004;140:554–6.
21.
Zurück zum Zitat Adams Jr HP. Secondary prevention of atherothrombotic events after ischemic stroke. Mayo Clin Proc. 2009;84:43–51.PubMedCrossRef Adams Jr HP. Secondary prevention of atherothrombotic events after ischemic stroke. Mayo Clin Proc. 2009;84:43–51.PubMedCrossRef
22.
Zurück zum Zitat Progress Collaborative Group. Randomised trial of a perindopril based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–41.CrossRef Progress Collaborative Group. Randomised trial of a perindopril based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–41.CrossRef
23.
Zurück zum Zitat Schrader J, Luders S, Kulschewski A, et al. Mortality and morbidity after stroke—eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218–26.PubMedCrossRef Schrader J, Luders S, Kulschewski A, et al. Mortality and morbidity after stroke—eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218–26.PubMedCrossRef
24.
Zurück zum Zitat Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2007;38:3198–204.PubMedCrossRef Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2007;38:3198–204.PubMedCrossRef
25.
Zurück zum Zitat Amarenco P, Benavente O, Goldstein LB, Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke. 2009;40:1405–9.PubMedCrossRef Amarenco P, Benavente O, Goldstein LB, Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke. 2009;40:1405–9.PubMedCrossRef
26.•
Zurück zum Zitat Martínez-Sánchez P, Rivera-Ordóñez C, et al. The beneficial effect of statins treatment by stroke subtype. Eur J Neurol. 2009;16:127–33.PubMedCrossRef Martínez-Sánchez P, Rivera-Ordóñez C, et al. The beneficial effect of statins treatment by stroke subtype. Eur J Neurol. 2009;16:127–33.PubMedCrossRef
27.
Zurück zum Zitat Fuentes B, Martínez-Sánchez P, Díez-Tejedor E. Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome. Cerebrovasc Dis. 2009;27 Suppl 1:126–33.PubMedCrossRef Fuentes B, Martínez-Sánchez P, Díez-Tejedor E. Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome. Cerebrovasc Dis. 2009;27 Suppl 1:126–33.PubMedCrossRef
28.
Zurück zum Zitat CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–39.CrossRef CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–39.CrossRef
29.•
Zurück zum Zitat Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol. 2010;9:273–84.PubMedCrossRef Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol. 2010;9:273–84.PubMedCrossRef
30.
Zurück zum Zitat Diener H, Bogousslavsky J, Brass L, et al. Acetylsalicylic acid on a background of clopidogrel in high-risk patients randomised after recent ischaemic stroke or transient ischaemic attack: the MATCH trial results. Lancet. 2004;364:331–4.PubMedCrossRef Diener H, Bogousslavsky J, Brass L, et al. Acetylsalicylic acid on a background of clopidogrel in high-risk patients randomised after recent ischaemic stroke or transient ischaemic attack: the MATCH trial results. Lancet. 2004;364:331–4.PubMedCrossRef
31.
Zurück zum Zitat Bhatt D, Fox K, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–17.PubMedCrossRef Bhatt D, Fox K, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–17.PubMedCrossRef
32.
Zurück zum Zitat Diener HC, Darius H, Bertrand-Hardy JM, et al. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract. 2001;55:162–3.PubMed Diener HC, Darius H, Bertrand-Hardy JM, et al. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract. 2001;55:162–3.PubMed
33.
Zurück zum Zitat Sacco RL, Diener HC, Yusuf S, PROFESS Study Group, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238–51.PubMedCrossRef Sacco RL, Diener HC, Yusuf S, PROFESS Study Group, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238–51.PubMedCrossRef
34.
Zurück zum Zitat Guiu JM, Ferro JM, Alvarez Sabin J, et al. Comparison of Triflusal and Aspirin for prevention of vascular events in patients after cerebral infarction. The TACIP study: a randomized, double blind, multicenter study. Stroke. 2003;34:840–8.CrossRef Guiu JM, Ferro JM, Alvarez Sabin J, et al. Comparison of Triflusal and Aspirin for prevention of vascular events in patients after cerebral infarction. The TACIP study: a randomized, double blind, multicenter study. Stroke. 2003;34:840–8.CrossRef
35.
Zurück zum Zitat Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36:782–6.PubMedCrossRef Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36:782–6.PubMedCrossRef
36.
Zurück zum Zitat Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444–51.PubMedCrossRef Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444–51.PubMedCrossRef
37.
Zurück zum Zitat Chimowitz MI, Lynn MJ, Howlett-Smith H, for the WASID investigators, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352:1305–16.PubMedCrossRef Chimowitz MI, Lynn MJ, Howlett-Smith H, for the WASID investigators, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352:1305–16.PubMedCrossRef
38.••
Zurück zum Zitat Muengtaweepongsa S, Singh NN, Cruz-Flores S. Pontine warning syndrome: case series and review of literature. J Stroke Cerebrovasc Dis. 2010;19:353–6.PubMedCrossRef Muengtaweepongsa S, Singh NN, Cruz-Flores S. Pontine warning syndrome: case series and review of literature. J Stroke Cerebrovasc Dis. 2010;19:353–6.PubMedCrossRef
39.
Zurück zum Zitat Hacke W, Kaste M, Bluhmki E, ECASS Investigators, et al. Thrombolysis with alteplase 3–4.5 h after acute ischemic stroke. N Engl J Med. 2008;359:1317–29.PubMedCrossRef Hacke W, Kaste M, Bluhmki E, ECASS Investigators, et al. Thrombolysis with alteplase 3–4.5 h after acute ischemic stroke. N Engl J Med. 2008;359:1317–29.PubMedCrossRef
40.
Zurück zum Zitat Cocho D, Belvis R, Marti-Fabregas J, Bravo Y, Aleu A, Pagonabarraga J, et al. Does thrombolysis benefit patients with lacunar syndrome? Eur Neurol. 2006;55:70–3.PubMedCrossRef Cocho D, Belvis R, Marti-Fabregas J, Bravo Y, Aleu A, Pagonabarraga J, et al. Does thrombolysis benefit patients with lacunar syndrome? Eur Neurol. 2006;55:70–3.PubMedCrossRef
41.•
Zurück zum Zitat Vivanco-Hidalgo RM, Rodriguez-Campello A, Ois A, et al. Thrombolysis in capsular warning syndrome. Cerebrovasc Dis. 2008;25:508–10.PubMedCrossRef Vivanco-Hidalgo RM, Rodriguez-Campello A, Ois A, et al. Thrombolysis in capsular warning syndrome. Cerebrovasc Dis. 2008;25:508–10.PubMedCrossRef
42.••
Zurück zum Zitat Saposnik G, Noel de Tilly L, Caplan LR. Pontine warning syndrome. Arch Neurol. 2008;65:1375–7.PubMedCrossRef Saposnik G, Noel de Tilly L, Caplan LR. Pontine warning syndrome. Arch Neurol. 2008;65:1375–7.PubMedCrossRef
43.
Zurück zum Zitat Smith EE, Abdullah AR, Petkovska I, et al. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke. 2005;36:2497–9.PubMedCrossRef Smith EE, Abdullah AR, Petkovska I, et al. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke. 2005;36:2497–9.PubMedCrossRef
44.
Zurück zum Zitat Baumann CR, Baumgartner RW, Gandjour J, et al. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke. 2006;37:1332–3.PubMedCrossRef Baumann CR, Baumgartner RW, Gandjour J, et al. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke. 2006;37:1332–3.PubMedCrossRef
45.••
Zurück zum Zitat Lee SJ, Saver JL, Liebeskind DS, et al. Safety of intravenous fibrinolysis in imaging-confirmed single penetrator artery infarcts. Stroke. 2010;41:2587–91.PubMedCrossRef Lee SJ, Saver JL, Liebeskind DS, et al. Safety of intravenous fibrinolysis in imaging-confirmed single penetrator artery infarcts. Stroke. 2010;41:2587–91.PubMedCrossRef
46.
Zurück zum Zitat González Hernández A, Fabre Pi O, López Fernández JC, Díaz Nicolás S. Thrombolysis in capsular warning syndrome. Med Clin (Barc). 2010;134:612–3.CrossRef González Hernández A, Fabre Pi O, López Fernández JC, Díaz Nicolás S. Thrombolysis in capsular warning syndrome. Med Clin (Barc). 2010;134:612–3.CrossRef
47.
Metadaten
Titel
Basilar Branch Occlusion
verfasst von
Jaime Gállego Culleré, MD, PhD
María Elena Erro Aguirre, MD, PhD
Publikationsdatum
01.06.2011
Verlag
Current Science Inc.
Erschienen in
Current Treatment Options in Cardiovascular Medicine / Ausgabe 3/2011
Print ISSN: 1092-8464
Elektronische ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-011-0125-x

Weitere Artikel der Ausgabe 3/2011

Current Treatment Options in Cardiovascular Medicine 3/2011 Zur Ausgabe

Cerebrovascular Disease and Stroke

Dolichoectasia of the Intracranial Arteries

Cerebrovascular Disease and Stroke

Venous Angiomas

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.